Optimize Obesity Development: Endpoint Strategies for Early-phase Innovation to Late-phase Differentiation Webinar Replay
Join the featured experts in eCOA, cardiac safety and medical imaging to learn how phase-appropriate endpoint solutions that generate high-quality, informative data can support critical decisions. From detecting early safety and efficacy signals informing dose selection, go/no-go and study design decisions, to characterizing treatment benefit and risk building a differentiated, regulator-ready evidence package, implementing the right endpoint strategy and technologies is paramount. Watch to learn how an integrated, phase-appropriate endpoint strategy can help teams identify meaningful signals earlier, reduce development uncertainty and generate stronger evidence for regulatory review and product differentiation.
Watch this webinar to learn how to:
- Build a phase-appropriate endpoint strategy that integrates patient-reported outcomes, glucose monitoring technologies (BGM & CGM), cardiac and imaging data to support the critical decisions required across the development cycle
- Connect the subjective patient experience with objective glucose data by studying symptoms, medication timing, fasting status, rescue actions and connected glucose readings. Attendees will also learn how this data can reveal early safety, tolerability and efficacy signals, inform dose selection and study design and strengthen the late-phase treatment-benefit narrative
- Evolve cardiac safety assessments across development, from focused QTc and heart-rate evaluation in early safety trials to consistent, scalable collection of 12-lead ECG and blood-pressure data in later development
- Select the right imaging strategy for Phase II and Phase III trials evaluating obesity, body composition analysis, impact on fatty liver disease and the broader physiological effects of weight-loss therapies
- Generate differentiating evidence beyond the standard body weight and glycemic control measures leveraging innovation modalities such as MRI-PDFF, MR elastography, organ volumetry, visceral and subcutaneous adipose tissue analysis and functional MRI
